CY2171B1 - Liquid composition containing ondansetron - Google Patents

Liquid composition containing ondansetron

Info

Publication number
CY2171B1
CY2171B1 CY0000018A CY0000018A CY2171B1 CY 2171 B1 CY2171 B1 CY 2171B1 CY 0000018 A CY0000018 A CY 0000018A CY 0000018 A CY0000018 A CY 0000018A CY 2171 B1 CY2171 B1 CY 2171B1
Authority
CY
Cyprus
Prior art keywords
pct
liquid composition
composition containing
sec
pharmaceutically acceptable
Prior art date
Application number
CY0000018A
Other languages
English (en)
Inventor
Rene Gambhir
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2171(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of CY2171B1 publication Critical patent/CY2171B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CY0000018A 1994-11-22 2000-05-23 Liquid composition containing ondansetron CY2171B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (1)

Publication Number Publication Date
CY2171B1 true CY2171B1 (en) 2002-08-23

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0000018A CY2171B1 (en) 1994-11-22 2000-05-23 Liquid composition containing ondansetron

Country Status (33)

Country Link
US (1) US5854270A (hu)
EP (1) EP0792149B1 (hu)
JP (1) JP2965704B2 (hu)
KR (1) KR100292124B1 (hu)
CN (1) CN1108153C (hu)
AT (1) ATE196084T1 (hu)
AU (1) AU703932B2 (hu)
BE (1) BE1009458A5 (hu)
BR (1) BR9509807A (hu)
CA (1) CA2205546C (hu)
CY (1) CY2171B1 (hu)
CZ (1) CZ285187B6 (hu)
DE (1) DE69518767T2 (hu)
DK (1) DK0792149T3 (hu)
ES (1) ES2151083T3 (hu)
FI (1) FI119356B (hu)
FR (1) FR2727015B1 (hu)
GB (2) GB9423588D0 (hu)
GR (1) GR3034684T3 (hu)
HK (1) HK1009590A1 (hu)
HU (1) HU226947B1 (hu)
IE (1) IE950884A1 (hu)
IL (1) IL116083A (hu)
IT (1) IT1282353B1 (hu)
NO (1) NO306892B1 (hu)
NZ (1) NZ297879A (hu)
PL (1) PL181522B1 (hu)
PT (1) PT792149E (hu)
RU (1) RU2145853C1 (hu)
SI (1) SI0792149T1 (hu)
TW (1) TW413634B (hu)
WO (1) WO1996015786A2 (hu)
ZA (1) ZA959820B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
WO2001013909A2 (en) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
PL366150A1 (en) * 2000-10-30 2005-01-24 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
DK1499623T3 (da) * 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
CN1665803A (zh) * 2002-04-30 2005-09-07 特瓦药厂有限公司 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
EP2478099B1 (en) 2009-09-18 2019-06-05 Chase Pharmaceuticals Corporation Combination for treating alzheimer-type dementia
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920003064B1 (ko) * 1984-01-25 1992-04-13 글락소 그룹 리미티드 헤테로시클릭 화합물의 제조방법
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
GB2295317A (en) 1996-05-29
GR3034684T3 (en) 2001-01-31
AU4313596A (en) 1996-06-17
BR9509807A (pt) 1997-10-21
WO1996015786A3 (en) 1996-06-27
FI972168A0 (fi) 1997-05-21
SI0792149T1 (en) 2001-02-28
KR100292124B1 (ko) 2001-07-12
HUT77944A (hu) 1998-12-28
TW413634B (en) 2000-12-01
KR970706815A (ko) 1997-12-01
IE950884A1 (en) 1996-05-29
IL116083A (en) 2000-09-28
DE69518767D1 (de) 2000-10-12
NO972324D0 (no) 1997-05-21
FR2727015B1 (fr) 1997-08-22
HU226947B1 (en) 2010-03-29
DK0792149T3 (da) 2000-12-18
FI972168A (fi) 1997-05-21
MX9703734A (es) 1997-09-30
PL320288A1 (en) 1997-09-15
AU703932B2 (en) 1999-04-01
FI119356B (fi) 2008-10-31
IL116083A0 (en) 1996-01-31
IT1282353B1 (it) 1998-03-20
CZ154897A3 (en) 1997-10-15
CN1171740A (zh) 1998-01-28
EP0792149B1 (en) 2000-09-06
BE1009458A5 (fr) 1997-04-01
DE69518767T2 (de) 2001-05-31
NO306892B1 (no) 2000-01-10
NO972324L (no) 1997-07-21
ATE196084T1 (de) 2000-09-15
JP2965704B2 (ja) 1999-10-18
GB9423588D0 (en) 1995-01-11
ES2151083T3 (es) 2000-12-16
CN1108153C (zh) 2003-05-14
EP0792149A2 (en) 1997-09-03
ZA959820B (en) 1996-07-29
CZ285187B6 (cs) 1999-06-16
HK1009590A1 (en) 1999-06-04
JPH10508866A (ja) 1998-09-02
PT792149E (pt) 2001-02-28
PL181522B1 (en) 2001-08-31
GB2295317B (en) 1998-11-25
CA2205546C (en) 2000-01-25
US5854270A (en) 1998-12-29
NZ297879A (en) 1998-12-23
ITRM950763A1 (it) 1997-05-20
CA2205546A1 (en) 1996-05-30
GB9523666D0 (en) 1996-01-24
FR2727015A1 (fr) 1996-05-24
WO1996015786A2 (en) 1996-05-30
RU2145853C1 (ru) 2000-02-27
ITRM950763A0 (hu) 1995-11-20

Similar Documents

Publication Publication Date Title
GB2295317B (en) Liquid composition containing ondansetron
GB2295318B (en) Freeze-dried dosage form containing ondansetron
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
ES2196079T3 (es) Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine